Literature DB >> 22627602

Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization.

Zhen Li1, Susanne Bonekamp, Vivek Gowdra Halappa, Celia Pamela Corona-Villalobos, Timothy Pawlik, Nik Bhagat, Diane Reyes, Hong Lai, Jean F Geschwind, Ihab R Kamel.   

Abstract

PURPOSE: To assess early response to transarterial chemoembolization by using volumetric functional magnetic resonance (MR) imaging in patients with islet cell liver metastases (ICLMs).
MATERIALS AND METHODS: This retrospective institutional review board-approved HIPAA-compliant study included 215 ICLMs in 26 patients (15 men, 11 women; mean age, 59.7 years; age range, 37-79 years). Volumetric measurements were performed by an experienced radiologist on diffusion-weighted and contrast material-enhanced MR images at baseline and 1-month follow-up. Measurements included mean change (three-dimensional [3D] mean apparent diffusion coefficient [ADC], 3D mean enhancement) and percentage of tumor with change above a predetermined threshold (3D threshold ADC, 3D threshold enhancement). Response by volumetric measurements at 1-month follow-up was compared with Response Evaluation Criteria in Solid Tumors (RECIST) at 6-month follow-up. Lesions that had complete or partial response were considered responders, while those with stable or progressive disease were considered nonresponders. Statistical analysis included the t test, receiver operating characteristic (ROC) curve analysis, and logistic regression analysis.
RESULTS: RECIST criteria at 6-month follow-up indicated 78 (36.3%) lesions responded, while 137 (63.7%) did not. The increase in 3D mean ADC was significantly higher in responders than in nonresponders (median, 26.2% vs 10.9%; P<.001). The 3D threshold ADC was 71.1% in responders and 47.6% in nonresponders (P<.001). Decrease in 3D mean arterial enhancement (AE) was significantly higher in responders than in nonresponders (median, 40.5% vs 18.0%; P<.001). Decrease in 3D mean venous enhancement (VE) was significantly higher in responders than in nonresponders (median, 28.0% vs 10.0%; P<.001). The 3D threshold VE and 3D threshold AE did not differ between responders and nonresponders. In unadjusted logistic regression analyses, 3D mean ADC and 3D threshold ADC had the highest odds ratio (1.02 and 1.03, respectively) and the largest area under the ROC curve (0.698 and 0.695, respectively).
CONCLUSION: Volumetric functional MR imaging could be used to predict early response of hepatic ICLMs to therapy and to distinguish between responders and nonresponders. © RSNA, 2012.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22627602     DOI: 10.1148/radiol.12112161

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  17 in total

1.  Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma.

Authors:  Celia Pamela Corona-Villalobos; Vivek Gowdra Halappa; Susanne Bonekamp; John Eng; Diane Reyes; David Cosgrove; Neda Rastegar; Li Pan; Timothy M Pawlik; Ihab R Kamel
Journal:  Invest Radiol       Date:  2015-04       Impact factor: 6.016

Review 2.  Added value of diffusion-weighted acquisitions in MRI of the abdomen and pelvis.

Authors:  William A Moore; Gaurav Khatri; Ananth J Madhuranthakam; Robert D Sims; Ivan Pedrosa
Journal:  AJR Am J Roentgenol       Date:  2014-05       Impact factor: 3.959

3.  Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization.

Authors:  Yan Luo; Sanaz Ameli; Ankur Pandey; Pegah Khoshpouri; Mounes Aliyari Ghasabeh; Pallavi Pandey; Zhen Li; Daoyu Hu; Ihab R Kamel
Journal:  Eur Radiol       Date:  2019-05-09       Impact factor: 5.315

4.  Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma.

Authors:  David Bonekamp; Susanne Bonekamp; Vivek Gowdra Halappa; Jean-Francois H Geschwind; John Eng; Celia Pamela Corona-Villalobos; Timothy M Pawlik; Ihab R Kamel
Journal:  Eur J Radiol       Date:  2013-12-03       Impact factor: 3.528

Review 5.  Prognostication and response assessment in liver and pancreatic tumors: The new imaging.

Authors:  Riccardo De Robertis; Paolo Tinazzi Martini; Emanuele Demozzi; Gino Puntel; Silvia Ortolani; Sara Cingarlini; Andrea Ruzzenente; Alfredo Guglielmi; Giampaolo Tortora; Claudio Bassi; Paolo Pederzoli; Mirko D'Onofrio
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

Review 6.  Update on the role of imaging in management of metastatic colorectal cancer.

Authors:  Sree Harsha Tirumani; Kyung Won Kim; Mizuki Nishino; Stephanie A Howard; Katherine M Krajewski; Jyothi P Jagannathan; James M Cleary; Nikhil H Ramaiya; Atul B Shinagare
Journal:  Radiographics       Date:  2014 Nov-Dec       Impact factor: 5.333

Review 7.  Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI.

Authors:  Julius Chapiro; MingDe Lin; Rafael Duran; Rüdiger E Schernthaner; Jean-François Geschwind
Journal:  Expert Rev Anticancer Ther       Date:  2014-11-05       Impact factor: 4.512

8.  Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival?

Authors:  Sonia Sahu; Ruediger Schernthaner; Roberto Ardon; Julius Chapiro; Yan Zhao; Jae Ho Sohn; Florian Fleckenstein; MingDe Lin; Jean-François Geschwind; Rafael Duran
Journal:  Radiology       Date:  2016-11-10       Impact factor: 11.105

9.  Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria.

Authors:  Susanne Bonekamp; Zhen Li; Jean-François H Geschwind; Vivek Gowdra Halappa; Celia Pamela Corona-Villalobos; Diane Reyes; Timothy M Pawlik; David Bonekamp; John Eng; Ihab R Kamel
Journal:  Radiology       Date:  2013-04-24       Impact factor: 11.105

Review 10.  Liver transarterial embolizations in metastatic neuroendocrine tumors.

Authors:  Louis de Mestier; Magaly Zappa; Olivia Hentic; Valérie Vilgrain; Philippe Ruszniewski
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.